Capricor Stock in Focus Ahead of FDA Decision on Duchenne Therapy Deramiocel
Capricor Therapeutics shares were in focus Wednesday as investors positioned ahead of the FDA’s Nov. 22 decision on deramiocel, the company’s cell therapy for Duchenne muscular dystrophy.
Why it matters — The FDA decision is a key near-term event for investors following Capricor and deramiocel.